US reimbursement for TAVI is boost for Edwards but market may remain tough
This article was originally published in Clinica
Executive Summary
Edwards Lifesciences' Sapien transcatheter heart valve is to be reimbursed in the US in patients with severe symptomatic aortic stenosis unable to undergo open heart surgery. Edwards' share price on the New York Stock Exchange closed up 2% at $84.78 on 1 May when the decision by the US Centers for Medicare and Medicaid Services (CMS) was announced.